Paul da Silva Jardine


Paul Da Silva Jardine is an expert in drug development in the cardiovascular field. He is a former VP at Pfizer R & D who spent more than 24 years at Pfizer managing project teams delivering over 50 clinical candidates in cardiovascular, obesity, diabetes, and osteoporosis. He discovered Lasofoxifene and led early clinical development team to an approved compound in Europe. Most recently, he was VP for Research in the Cardiovascular and Metabolic Diseases (CVMED) Research Unit at Pfizer responsible for projects from target identification in the end of Phase 2. After his career at Pfizer, Paul co-founded Staten Biotech (portfolio company of BGV) where is currently the CSO and he is involved in the creation of other BGV portfolio companies.